



SUPPLEMENTAL MATERIAL

Appendix A

Supplemental Figure I. Distribution of CTP ischemic core volume (CBV <1.2 mL/100mL) for each Alberta Stroke Program Early CT Score (ASPECTS) category. The estimated core volume on perfusion imaging varied within the same ASPECTS.



Supplemental Figure II. Distribution of CTP ischemic core volume (CBV <1.2 mL/100mL) for each CTA collateral score (CTA-CS) category. CTP ischemic core volumes were larger in patients with lower collateral scores. A higher degree of discordance was observed for lower CTA-CS with larger CTP ischemic core volumes.



Supplemental Table I. Univariable analysis of poor functional outcome (mRS 5-6). ASPECTS, Alberta Stroke Program Early CT Score; CTA-CS; Computed Tomography Angiography Collateral Score; IVT, intravenous alteplase; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, Odds Ratio.


Variables	OR (95% CI)	P value
CTP ischemic core volume (per 10 mL)	1.03 (1.02-1.05)	<0.01
CTA-CS	0.93 (0.85-1.00)	0.07
ASPECTS	0.98 (0.95-1.02)	0.43
Age (per year)	0.93 (0.85-1.00)	0.07
NIHSS (per point)	0.98 (0.95-1.02)	0.43
Male sex (vs. female)	0.88 (0.78-1.00)	0.04
IVT	0.98 (0.85-1.12)	0.70
Onset-to-groin time (per 10 min)	1.01 (1.00- 1.01)	0.06
Pre-mRS	1.16 (1.10-1.21)	<0.01
Occlusion location	0.94 (0.86-1.02)	0.15

Supplemental Table II. Multivariable analysis of poor functional outcome (mRS 5-6).


ASPECTS, Alberta Stroke Program Early CT Score; CTA-CS; Computed Tomography Angiography Collateral Score; IVT, intravenous alteplase; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; aOR, adjusted Odds Ratio.

Variables	aOR (95% CI)	P value
CTP ischemic core volume (per 10 mL)	1.03(1.02-1.05)	<0.01
NIHSS (per point)	1.00 (0.99-1.01)	0.93
Pre-mRS	1.11 (1.05-1.16)	< 0.01
Male sex (vs. female)	0.90 (0.81-1.00)	0.09
Age (per year)	1.01 (1.01-1.01)	<0.01
IVT	1.07 (0.94-1.20)	0.23
Onset-to-groin time (per 10 min)	1.00 (0.99-1.01)	0.08
Occlusion location	0.96 (0.88-1.02)	0.34
CTA-CS	0.96 (0.90-1.04)	0.29
NIHSS (per point)	1.00 (0.99-1.01)	0.56
Pre-mRS	1.12 (1.06-1.17)	<0.01
Male sex (vs. female)	0.93 (0.83-1.03)	0.20
Age (per year)	1.01 (1.01-1.01)	<0.01
IVT	1.08 (0.95-1.21)	0.22
Onset-to-groin time (per 10 min)	1.00 (1.00-1.01)	0.10
Occlusion location	0.95 (0.87-1.01)	0.19
ASPECTS	0.98 (0.96-1.02)	0.34
NIHSS (per point)	1.00 (0.99-1.01)	0.40
Pre-mRS	1.11 (1.06-1.16)	<0.01
Male sex (vs. female)	0.93 (0.83-1.03)	0.17
Age (per year)	1.01 (1.01-1.01)	<0.01
IVT	1.09 (0.96-1.22)	0.16
Onset-to-groin time (per 10 min)	1.00 (1.00-1.01)	0.16
Occlusion location	0.95 (0.87-1.01)	0.21

Supplemental Figure III. Distribution of the modified Rankin Scale (mRS) scores at 90 days for patients with CTP ischemic core volumes ≥ 70 mL versus <70 mL.



Supplemental Figure IV. Distribution of the modified Rankin Scale (mRS) scores at 90 days for patients with CTP ischemic core volumes ≥ 50 mL versus <50 mL.



Supplemental Table III. Functional outcome (mRS) at 90 days stratified by ischemic core volume (≥ 50 mL versus <50 mL). mRS, modified Rankin Scale

	≥ 50 mL	<50 mL	<i>P</i> value
Poor outcome (mRS 5-6) – n(%)	17(50)	34(22)	<0.01
Functional independence (mRS 0-2) – n(%)	4(12)	86(56)	<0.01
Mortality– n(%)	15(44)	23(15)	<0.01
sICH– n(%)	4(11)	4(2)	0.02

Supplemental Table IV. Association of imaging biomarkers with mortality and sICH.
 ASPECTS, Alberta Stroke Program Early CT Score; mRS, modified Rankin Scale;
 aOR, adjusted Odds Ratio.

	Mortality		sICH	
	aOR(95%CI)	<i>P</i> value	aOR(95%CI)	<i>P</i> value
CTP ischemic core volume (per 10 mL)	1.03(1.01-1.04)	<0.01	1.01(1.01-1.02)	<0.01
CTA-CS	0.95(0.88-1.02)	0.14	0.96(0.92-0.99)	0.02
ASPECTS	0.98(0.95-1.01)	0.22	0.99(0.97-1.01)	0.15

Appendix B

MR CLEAN Registry Investigators – group authors

Executive committee

Diederik W.J. Dippel¹; Aad van der Lugt²; Charles B.L.M. Majoie³; Yvo B.W.E.M. Roos⁴; Robert J. van Oostenbrugge⁵; Wim H. van Zwam⁶; Jelis Boiten¹⁴; Jan Albert Vos⁸

Study coordinators

Ivo G.H. Jansen³; Maxim J.H.L. Mulder^{1,2}; Robert- Jan B. Goldhoorn^{5,6}; Kars C.J. Compagne²; Manon Kappelhof³; Josje Brouwer⁴; Sanne J. den Hartog^{1,2,40}; Wouter H. Hinsenveld^{5,6};

Local principal investigators

Diederik W.J. Dippel¹; Bob Roozenbeek¹; Aad van der Lugt²; Adriaan C.G.M. van Es²; Charles B.L.M. Majoie³; Yvo B.W.E.M. Roos⁴; Bart J. Emmer³; Jonathan M. Coutinho⁴; Wouter J. Schonewille⁷; Jan Albert Vos⁸; Marieke J.H. Wermer⁹; Marianne A.A. van Walderveen¹⁰; Julie Staals⁵; Robert J. van Oostenbrugge⁵; Wim H. van Zwam⁶; Jeannette Hofmeijer¹¹; Jasper M. Martens¹²; Geert J. Lycklama à Nijeholt¹³; Jelis Boiten¹⁴; Sebastiaan F. de Bruijn¹⁵; Lukas C. van Dijk¹⁶; H. Bart van der Worp¹⁷; Rob H. Lo¹⁸; Ewoud J. van Dijk¹⁹; Hieronymus D. Boogaarts²⁰; J. de Vries²²; Paul L.M. de Kort²¹; Julia van Tuijl²¹; Jo P. Peluso²⁶; Puck Fransen²²; Jan S.P. van den Berg²²; Boudewijn A.A.M. van Hasselt²³; Leo A.M. Aerden²⁴; René J. Dallinga²⁵; Maarten Uyttenboogaart²⁸; Omid Eschgi²⁹; Reinoud P.H. Bokkers²⁹; Tobien H.C.M.L. Schreuder³⁰; Roel J.J. Heijboer³¹; Koos Keizer³²; Lonke S.F. Yo³³; Heleen M. den Hertog²²; Tomas Bulut³⁵; Paul J.A.M. Brouwers³⁴

Imaging assessment committee

Charles B.L.M. Majoie³(chair); Wim H. van Zwam⁶; Aad van der Lugt²; Geert J. Lycklama à Nijeholt¹³; Marianne A.A. van Walderveen¹⁰; Marieke E.S. Sprengers³; Sjoerd F.M. Jenniskens²⁷; René van den Berg³; Albert J. Yoo³⁸; Ludo F.M. Beenen³; Alida A. Postma⁶; Stefan D. Roosendaal³; Bas F.W. van der Kallen¹³; Ido R. van den Wijngaard¹³; Adriaan C.G.M. van Es²; Bart J. Emmer³; Jasper M. Martens¹²; Lonke S.F. Yo³³; Jan Albert Vos⁸; Joost Bot³⁶; Pieter-Jan van Doormaal²; Anton Meijer²⁷; Elyas Ghariq¹³; Reinoud P.H. Bokkers²⁹; Marc P. van Proosdij³⁷; G. Menno Krietemeijer³³; Jo P. Peluso²⁶; Hieronymus D. Boogaarts²⁰; Rob Lo¹⁸; Dick Gerrits³⁵; Wouter Dinkelaar²; Auke P.A. Appelman²⁹; Bas Hammer¹⁶; Sjoert Pegge²⁷; Anouk van der Hoorn²⁹; Saman Vinke²⁰.

Writing committee

Diederik W.J. Dippel¹(chair); Aad van der Lugt²; Charles B.L.M. Majoie³; Yvo B.W.E.M. Roos⁴; Robert J. van Oostenbrugge⁵; Wim H. van Zwam⁶; Geert J. Lycklama à Nijeholt¹³; Jelis Boiten¹⁴; Jan Albert Vos⁸; Wouter J. Schonewille⁷; Jeannette Hofmeijer¹¹; Jasper M. Martens¹²; H. Bart van der Worp¹⁷; Rob H. Lo¹⁸

Adverse event committee

Robert J. van Oostenbrugge⁵(chair); Jeannette Hofmeijer¹¹; H. Zwenneke Flach²³

Trial methodologist

Hester F. Lingsma⁴⁰

Research nurses / local trial coordinators

Naziha el Ghannouti¹; Martin Sterrenberg¹; Wilma Pellikaan⁷; Rita Sprengers⁴; Marjan Elfrink¹¹; Michelle Simons¹¹; Marjolein Vossers¹²; Joke de Meris¹⁴; Tamara Vermeulen¹⁴; Annet Geerlings¹⁹; Gina van Vemde²²; Tiny Simons³⁰; Gert Messchendorp²⁸; Nynke Nicolaij²⁸; Hester Bongenaar³²; Karin Bodde²⁴; Sandra Kleijn³⁴; Jasmijn Lodico³⁴; Hanneke Droste³⁴; Maureen Wollaert⁵; Sabrina Verheesen⁵; D. Jeurrissen⁵; Erna Bos⁹; Yvonne Drabbe¹⁵; Michelle Sandiman¹⁵; Nicoline Aldering¹¹; Berber Zweedijk¹⁷; Jocova Vervoort²¹; Eva Ponjee²²; Sharon Romviel¹⁹; Karin Kanselaar¹⁹; Denn Barning¹⁰.

PhD / Medical students:

Esmee Venema⁴⁰; Vicky Chalos^{1,40}; Ralph R. Geuskens³; Tim van Straaten¹⁹; Saliha Ergezen¹; Roger R.M. Harmsma¹; Daan Muijres¹; Anouk de Jong¹; Olvert A. Berkhemer^{1,3,6}; Anna M.M. Boers^{3,39}; J. Huguet³; P.F.C. Groot³; Marieke A. Mens³; Katinka R. van Kranendonk³; Kilian M. Treurniet³; Manon L. Tolhuisen^{3,39}; Heitor Alves³; Annick J. Weterings³; Eleonora L.F. Kirkels³; Eva J.H.F. Voogd¹¹; Lieve M. Schupp³; Sabine L. Collette^{28,29}; Adrien E.D. Groot⁴; Natalie E. LeCouffe⁴; Praneeta R. Konduri³⁹; Haryadi Prasetya³⁹; Nerea Arrarte-Terreros³⁹; Lucas A. Ramos³⁹.

List of affiliations

Department of Neurology¹, Radiology², Public Health⁴⁰, Erasmus MC University Medical Center;

Department of Radiology and Nuclear Medicine³, Neurology⁴, Biomedical Engineering & Physics³⁹, Amsterdam UMC, University of Amsterdam, Amsterdam;

Department of Neurology⁵, Radiology⁶, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM);

Department of Neurology⁷, Radiology⁸, Sint Antonius Hospital, Nieuwegein;

Department of Neurology⁹, Radiology¹⁰, Leiden University Medical Center;

Department of Neurology¹¹, Radiology¹², Rijnstate Hospital, Arnhem;

Department of Radiology¹³, Neurology¹⁴, Haaglanden MC, the Hague;

Department of Neurology¹⁵, Radiology¹⁶, HAGA Hospital, the Hague;

Department of Neurology¹⁷, Radiology¹⁸, University Medical Center Utrecht;

Department of Neurology¹⁹, Neurosurgery²⁰, Radiology²⁷, Radboud University Medical Center, Nijmegen;

Department of Neurology²¹, Radiology²⁶, Elisabeth-TweeSteden ziekenhuis, Tilburg;

Department of Neurology²², Radiology²³, Isala Klinieken, Zwolle;

Department of Neurology²⁴, Radiology²⁵, Reinier de Graaf Gasthuis, Delft;

Department of Neurology²⁸, Radiology²⁹, University Medical Center Groningen;

Department of Neurology³⁰, Radiology³¹, Atrium Medical Center, Heerlen;

Department of Neurology³², Radiology³³, Catharina Hospital, Eindhoven;

Department of Neurology³⁴, Radiology³⁵, Medisch Spectrum Twente, Enschede;

Department of Radiology³⁶, Amsterdam UMC, Vrije Universiteit van Amsterdam, Amsterdam;

Department of Radiology³⁷, Noordwest Ziekenhuisgroep, Alkmaar;

Department of Radiology³⁸, Texas Stroke Institute, Texas, United States of America.